A large multicenter clinical trial published in JAMA Surgery shows that a gene expression profile–based test can reliably identify melanoma patients who have a low risk of cancer spreading to their lymph nodes.

The findings could help guide decisions about whether to perform sentinel lymph node biopsy, a standard but invasive staging procedure.

The MERLIN_001 trial evaluated the clinicopathologic gene expression profile test  in more than 1,700 patients with early-stage melanoma at nine U.S. cancer centres, including Moffitt Cancer Centre.

The blinded, prospective study found that the test accurately stratified patients by their likelihood of having sentinel lymph node metastasis, a key factor in treatment planning and prognosis.

“This study represents a major step forward in evaluating personalised melanoma care,” said Vernon Sondak, M.D., principal investigator and chair of the Cutaneous Oncology Department at Moffitt.

“Our results show that the clinicopathologic gene expression profile test adds a level of accuracy above current clinical factors alone, even when factors like mitotic rate and histologic subtype are taken into account, and this kind of knowledge ultimately allows patients and surgeons to make better decisions about when sentinel node biopsy should be part of the management of clinically localised melanoma. In appropriately selected patients, this test can add value for shared decision-making.”

Refining Risk to Inform Surgical Decisions 

Current melanoma guidelines recommend sentinel lymph node biopsy for patients with a predicted risk of nodal metastasis greater than 10%, and consider the procedure when the risk is between 5% and 10%.

The clinicopathologic gene expression profile test combines a gene signature with clinical factors such as tumour thickness and patient age to classify risk as low or high.

In the trial:

• 37% of patients were classified as low risk by the test. 

• The rate of sentinel node positivity among low-risk patients was 7.1%, compared with 23.8% in the high-risk group. 

• Negative predictive value for low-risk cases was 92.9%. 

• The test performed consistently across tumour sites, histologic subtypes and age groups. 

• Nearly half of patients aged 65 or older were classified as low risk, with a 6.6% nodal positivity rate, more than three times lower than high-risk cases.

Sentinel lymph node biopsy is used to guide treatment decisions, including the use of adjuvant immunotherapy and surveillance intensity.

However, the procedure adds cost, potential complications and recovery time for patients who may not benefit.

A predictive test could help reduce the number of node-negative sentinel lymph node biopsies performed each year without compromising patient outcomes.

“This trial marks a milestone in our ability to personalise melanoma treatment by integrating gene expression profile testing with clinical decision-making,” said Jonathan Zager, M.D., contributing author of the study and surgical oncologist in the Cutaneous Oncology Department at Moffitt.

“By helping identify who’s truly low risk for lymph node metastasis, the Merlin assay allows us as clinicians to make more informed, evidence-based choices and potentially spare some patients an unnecessary procedure and the general anaesthesia that goes along with it.”

Article: Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status

Source: H. Lee Moffitt Cancer Center & Research Institute